8/7/2020  9:59:50 PM Chg. +0.13 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
620.66USD +0.02% 18,533
Turnover: 11.51 mill.
-Bid Size: - -Ask Size: - 65.99 bill.USD 0.00% 32.00

Business description

Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain, and infectious diseases.
 

Management board & Supervisory board

CEO
Dr. Leonard S. Schleifer
Management board
Robert E. Landry, Dr. George D. Yancopoulos
Supervisory board
P. Roy Vagelos, M.D., Arthur F. Ryan, Christine A. Poon, Dr. Bonnie L. Bassler, Dr. George D. Yancopoulos, Dr. Leonard S. Schleifer, Dr. Marc Tessier-Lavigne, George L. Sing, Huda Y. Zoghbi, M.D., Joseph L. Goldstein, M.D., Michael S. Brown, M.D., Tony Coles, M.D.
 

Company data

Name: Regeneron Pharmaceuticals Inc.
Address: 777 Old Saw Mill River Road,Tarrytown, New York 10591-6707, USA
Phone: +1-914-847-7000
Fax: -
E-mail: -
Internet: is.gd/sEAmh8
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 60.40%
IPO date: -

Investor relations

Name: -
IR phone: +1-914-847-7741
IR Fax: -
IR e-mail: invest@regeneron.com

Main Shareholders

Freefloat
 
60.40%
Sanofi
 
21.00%
Capital World Investors
 
7.50%
The Vanguard Group, Inc.
 
5.60%
BlackRock, Inc.
 
5.50%